Due to its long-standing connection to cancer development, and the fact that the BRM/BRG complexes control the expression of many cancer-associated genes, there have been several recent studies that report the use of small-molecule inhibitors to target SMARCA2/4 bromodomains. This evidence concerns the gene SMARCA2 and cancer.